Genprex, Inc. announced that on March 18, 2026, its research collaborators will present positive preclinical data on its lead drug, Reqorsa, at the AACR Annual Meeting on April 17-22, detailing significant findings about lung cancer treatment biomarkers and effectiveness against tumors. The studies showed that 50% of certain non-small cell lung cancer models exhibited resistance to the therapy, and the combined treatment with alectinib led to a 79% tumor shrinkage in sensitive models.